Pressure BioSciences (PBIO) 10-Q 12 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 10, 2015
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830,656
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		21,485,654
Trading Symbol	PBIO
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 76,875	$ 473,948
Accounts receivable	362,822	272,022
Inventories, net of $50,000 reserve at September 30, 2015 and December 31, 2014	808,843	850,552
Prepaid income taxes	7,381	7,381
Prepaid expenses and other current assets	74,396	104,204
Total current assets	1,330,317	$ 1,708,107
Investment in available-for-sale equity securities	322,860
Debt issuance costs, net	533,403
Property and equipment, net	24,408	$ 36,025
TOTAL ASSETS	2,210,988	1,744,132
CURRENT LIABILITIES
Accounts payable	834,812	1,035,781
Accrued employee compensation	205,953	157,347
Accrued professional fees and other	837,052	719,432
Deferred revenue	101,421	27,117
Convertible debt, net of debt discount of $375,378 and $328,681, respectively	296,818	1,004,513
Other debt, net of discount of $4,676 and $0, respectively	246,036	80,480
Warrant derivative liability	1,541,130	159,875
Conversion option liability	2,227,330	590,341
Total current liabilities	6,290,552	$ 3,774,886
LONG TERM LIABILITIES
Convertible debt, net of debt discount of $3,297,994	$ 412,325
Deferred revenue		$ 28,977
TOTAL LIABILITIES	$ 6,702,877	$ 3,803,863
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 21,319,131 and 18,673,390 shares issued and outstanding on September 30, 2015 and December 31, 2014, respectively	$ 213,192	$ 186,734
Warrants to acquire common stock	5,347,054	5,253,566
Additional paid-in capital	25,594,074	$ 24,617,564
Accumulated other comprehensive income	(76,687)
Accumulated deficit	(35,570,641)	$ (32,118,714)
Total stockholders' deficit	(4,491,889)	(2,059,731)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	2,210,988	1,744,132
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	866	866
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 100	$ 100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 36	$ 36
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, value	$ 114	$ 114

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventories reserve	$ 50,000	$ 50,000
Convertible debt discount current	375,378	328,681
Other debt net of discount	4,676	$ 0
Convertible debt discount non current	$ 3,297,994
Convertible preferred stock, par value	$ 0.01
Convertible preferred stock, authorized	1,000,000
Convertible preferred stock, shares issued	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	21,319,131	18,673,390
Common stock, shares outstanding	21,319,131	18,673,390
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	86,570	86,570
Convertible preferred stock, shares outstanding	86,570	86,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,546	3,546
Convertible preferred stock, shares outstanding	3,546	3,546
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	11,416	11,416
Convertible preferred stock, shares outstanding	11,416	11,416

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Products, services, other	$ 481,452	$ 372,545	$ 1,174,391	$ 1,084,156
Grant revenue	98,882		259,181
Total revenue	580,334	$ 372,545	1,433,572	$ 1,084,156
Costs and expenses:
Cost of products and services	209,804	149,065	575,780	461,124
Research and development	355,574	232,032	878,899	716,358
Selling and marketing	207,888	188,129	574,289	555,543
General and administrative	497,796	600,952	2,034,040	1,777,887
Total operating costs and expenses	1,271,062	1,170,178	4,063,008	3,510,912
Operating loss	(690,728)	(797,633)	(2,629,436)	(2,426,756)
Other (expense) income:
Interest expense	$ (1,584,830)	(179,942)	(2,831,106)	(658,255)
Other expense		$ (80,102)	(513,352)	$ (80,102)
Gain on extinguishment of embedded derivative liabilities	$ 1,180,251		2,028,324
Change in fair value of derivative liabilities	437,379	$ 98,627	515,410	$ (156,779)
Total other (expense) income	32,800	(161,417)	(800,724)	(895,136)
Net loss	(657,928)	(959,050)	(3,430,160)	(3,321,892)
Accrued dividends on convertible preferred stock	$ 1,711	$ (43,362)	$ (21,768)	(97,955)
Deemed dividends on convertible preferred stock				(1,388,062)
Net loss applicable to common shareholders	$ (656,217)	$ (1,002,412)	$ (3,451,928)	$ (4,807,909)
Net loss per share attributable to common stockholders - basic and diluted	$ (0.03)	$ (0.07)	$ (0.17)	$ (0.35)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	20,737,827	15,238,466	19,771,323	13,648,795

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Comprehensive Loss
Net loss	$ (657,928)	$ (959,050)	$ (3,430,160)	$ (3,321,892)
Other comprehensive loss
Unrealized loss on marketable securities	(76,687)		(76,687)
Comprehensive loss	$ (734,615)	$ (959,050)	$ (3,506,847)	$ (3,321,892)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,430,160)	$ (3,321,892)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,279	59,364
Accretion of interest and amortization of debt discount and deferred financing fees	2,367,381	$ 611,919
Debt conversion option value in excess of debt	476,442
Stock-based compensation expense	185,370	$ 46,770
Amortization of third party fees paid in common stock and warrants	173,538	$ 206,226
Gain on extinguishment of embedded derivative liabilities	(2,028,324)
Change in fair value of derivative liabilities	(515,410)	$ 156,779
Changes in operating assets and liabilities:
Accounts receivable	(90,800)	(187,406)
Inventories	41,709	(115,847)
Prepaid expenses and other assets	123,808	222,041
Accounts payable	(200,969)	(16,976)
Accrued employee compensation	48,606	13,826
Deferred revenue and other accrued expenses	150,581	122,463
Net cash used in operating activities	(2,679,949)	(2,202,713)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property plant and equipment	(6,662)	(7,139)
Net cash used in investing activities	(6,662)	$ (7,139)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from related party debt	6,300
Payment of related party debt	(12,300)	$ (6,394)
Net proceeds from convertible debt	3,991,437	957,744
Payments on convertible debt	(2,107,065)	(303,100)
Net proceeds from non-convertible debt	1,300,000	270,252
Payments on non-convertible debt	(537,641)	$ (267,377)
Payment of prepayment penalty	$ (351,193)
Net proceeds from the issuance of common stock		$ 149,166
Net proceeds from the issuance of convertible preferred stock		1,476,360
Net cash provided by financing activities	$ 2,289,538	2,276,651
NET DECREASE IN CASH	(397,073)	66,799
CASH AT BEGINNING OF YEAR	473,948	31,417
CASH AT END OF PERIOD	76,875	98,216
SUPPLEMENTAL INFORMATION
Interest paid in cash	$ 239,389	$ 33,445
Income taxes paid in cash
NON CASH TRANSACTIONS:
Convertible debt exchanged for convertible preferred stock		$ 270,000
Accrued dividends on preferred stock	$ 21,768	97,955
Issuance of convertible preferred stock for interest		30,000
Issuance of convertible preferred stock for board of director and other fees		$ 92,750
Issuance of common stock for investment in available-for-sale equity securities	$ 399,547
Unrealized loss from available-for-sale equity securities	$ 76,687
Deemed dividend on convertible preferred stock		$ 1,388,062
Convertible debt and extension fee exchanged for common stock	$ 338,000	$ 87,500
Debt discount from derivative liability	5,085,536
Extension fees added to principal	84,000
Prepayment penalty and accrued interest enrolled into debt principal	$ 48,950
Common stock issued for preferred dividends		$ 82,231

Business Overview, Liquidity an

Business Overview, Liquidity and Management Plans	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview, Liquidity and Management Plans	1) Business Overview, Liquidity and Management Plans Pressure BioSciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming and, in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking – the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels i.e., 35,000 pounds per square inch (“ psi Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“ DNA RNA ® PULSE PCT SPS In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities but is expected to commence operations in 2016. Therefore, we don’t have control of the subsidiary and did not consolidate in our financial statements.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2015
Going Concern
Going Concern	2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of September 30, 2015, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Note 6, completed debt financing subsequent to September 30, 2015. We have financing efforts in place to continue to raise cash through debt and equity offerings. Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the nine months ended September 30, 2015 we received $5,952,053 net proceeds, in additional convertible and non-convertible debt. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. We need substantial additional capital to fund normal operations in future periods. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects. These financial statements do not include any adjustments that might result from this uncertainty.

Interim Financial Reporting

Interim Financial Reporting	9 Months Ended
	Sep. 30, 2015
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Reporting	3) Interim Financial Reporting The accompanying unaudited condensed consolidated financial statements of Pressure BioSciences, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles” or “GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all material adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 31, 2015.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4) Summary of Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates To prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2015 and 2014. For the Three Months Ended September 30, 2015 2014 Top Five Customers 43 % 53 % Federal Agencies 2 % 1 % For the Nine Months Ended September 30, 2015 2014 Top Five Customers 34 % 31 % Federal Agencies 14 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Top Five Customers 61 % 86 % Federal Agencies 1 % 9 % Product Supply BIT Group, Inc. of California has been our sole contract manufacturer for our PCT NEP3229 and NEP2320 instrumentation. However, the Company has reached agreement for a Massachusetts-based contract manufacturer to assemble its future builds of the NEP2320 instrument, effective in early 2016. Investment in Available-For-Sale Equity Securities As of September 30, 2015, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities” Debt Issuance Costs In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”, or ASU 2015-03. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. Costs incurred in obtaining debt funding are currently deferred and amortized on an effective interest method over the terms of the loans. Amortization expense for 2015 and 2014 was $41,085 and $0 respectively, and has been classified with interest expense in the consolidated financial statements. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2015 and 2014: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Numerator: Net loss $ (657,928 ) $ (959,050 ) $ (3,430,160 ) $ (3,321,892 ) Accrued dividend for Preferred Stock 1,711 (43,362 ) (21,768 ) (97,955 ) Deemed dividend on Series K Convertible Preferred Stock - - - (1,388,062 ) Net loss applicable to common shareholders $ (656,217 ) $ (1,002,412 ) $ (3,451,928 ) $ (4,807,909 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 20,737,827 15,238,466 19,771,323 13,648,795 Loss per common share - basic and diluted $ (0.03 ) $ (0.07 ) $ (0.17 ) $ (0.35 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. For the Nine Months Ended September 30, 2015 2014 Stock options 3,201,250 3,356,250 Convertible debt 26,015,029 4,091,151 Common stock warrants 26,125,127 17,895,717 Convertible preferred stock: Series D Convertible Preferred Stock 750,000 750,000 Series G Convertible Preferred Stock 865,700 865,700 Series H Convertible Preferred Stock 1,000,000 1,000,000 Series H2 Convertible Preferred Stock 2,100,000 - Series J Convertible Preferred Stock 3,546,000 3,548,000 Series K Convertible Preferred Stock 11,399,000 11,399,000 75,002,106 42,905,818 Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $74,864 and $6,387 for the three months ended September 30, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Three Months Ended September 30, 2015 2014 Research and development $ 18,307 $ 1,749 Selling and marketing 13,310 1,391 General and administrative 43,247 3,247 Total stock-based compensation expense $ 74,864 $ 6,387 We recognized stock-based compensation expense of $185,370 and $46,771 for the nine months ended September 30, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Nine Months Ended September 30, 2015 2014 Research and development $ 41,172 $ 19,602 Selling and marketing 27,386 13,296 General and administrative 116,812 13,873 Total stock-based compensation expense $ 185,370 $ 46,771 Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015. Fair value measurements at September 30, 2015 using: September 30, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2015 (Level 1) (Level 2) (Level 3) Series D Preferred Stock Purchase Warrants $ 122,692 - - $ 122,692 Available-For-Sale Equity Securities 322,860 322,860 - - Convertible Debt Warrants 1,418,438 - - 1,418,438 Conversion Option Liabilities 2,227,330 - - 2,227,330 Total Derivatives $ 4,091,320 $ 322,860 $ - $ 3,768,460 January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities September 30, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ (37,183 ) $ - $ 122,692 Convertible Debt Warrants - 1,418,927 (489 ) - 1,418,438 Conversion Option Liabilities 590,341 4,143,051 (477,738 ) (2,028,324 ) 2,227,330 Total Derivatives $ 750,216 $ 5,561,978 $ (515,410 ) $ (2,028,324 ) $ 3,768,460 The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2014 Warrants revalued at September 30, 2015 Expected life (in months) 60.0 22.0 13.0 Expected volatility 104.5 % 116.0 % 117.5 % Risk-free interest rate 0.875 % 0.58 % 0.33 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.15 $ 0.11 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the year reflected on a per share common stock equivalent basis. Assumptions For the three months ended September 30, 2015 Warrants revalued at September 30, 2015 Expected life (in months) 60.0 60.0 Expected volatility 118.3 - 120.1 % 136.5 -138.2 % Risk-free interest rate 1.48-1.69 % 1.37 % Exercise price $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$.21 $ 0.20 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at September 30, 2015 Expected life (in months) 6-24 0-18 2-21 Expected volatility 104.2-153.8% 86.9%-142.2% 88.6-130.6% Risk-free interest rate 0.05-0.99% 0.01-0.72% 0.01-0.64% Exercise price $0.10-$0.35 $0.10-$0.25 $0.11-$0.25 Fair value per conversion option $0.09-$0.28 $0.07-$0.26 $0.08-$0.16

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5) Commitments and Contingencies Operating Leases Our corporate offices are currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. In November 2007, we signed a lease agreement commencing in February 2008 pursuant to which we lease approximately 5,500 square feet of office space. We extended the lease term until December 31, 2015 with a monthly payment of $4,800. In September 2014 we moved to approximately 855 square feet of lab space in Medford, MA with a monthly payment of $3,094. Effective November 1, 2015, we entered into a revised lease with the addition of 833 additional square feet of lab and office space at the existing facility in Medford, MA. The new monthly payment is $5,385. The expiration of the new lease remains unchanged: December 31, 2017. Rental costs are expensed as incurred. During the nine months ended September 30, 2015 and Government Grants We have received a $1.05 million NIH SBIR Phase II Grant. Under the grant, the NIH has committed to pay the company to develop a high-throughput, high pressure-based DNA Shearing System for Next Generation Sequencing applications.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	6) Convertible Debt and Other Debt We have entered into various convertible debentures. The convertible debentures have terms ranging from 12 to 24 months and subject to annual interest rates ranging from 4% to 10%. The proceeds received are net of fees. The lenders charge interest per annum based on the principal balance. The lenders have the right, at any time after 180 days from the issue date to convert any or part of the outstanding and unpaid principal and interest into shares of the Company’s common stock based on a volume weighted average price of the closing prices of the Company’s shares during various periods prior to conversion subject to adjustments for stock splits, stock dividends or rights offerings. The Company shall have the right to prepay the debenture for a payment of the outstanding principal plus unpaid interest at any time on or before six months after the effective date. If the Company chooses to prepay it will incur pre-payment penalties ranging from 19% to 38% of the principal balance. The Company is required to reserve shares of common stock for full conversion of these debentures. The maturity dates range from six months to two years after the effective date of the payment. The Company determined that the conversion feature met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature on each debt agreement and accounted for it as a derivative liability. The fair value of the conversion feature was accounted for as a note discount and will be amortized to interest expense over the life of the loan. The fair value of the conversion feature was reflected in the conversion option liability line in the condensed consolidated balance sheet. The proceeds from these convertible debts were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in allocations to the convertible option and accounted for as a liability in the Company’s condensed consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds is offset by debt discounts which will be amortized to interest expense over the expected life of the debt. In connection with the senior secured convertible debentures issued in our still open private placement with closings in July 2015 and September 2015, we also issued warrants to the lenders to purchase an aggregate 5,857,142 shares of the Common Stock, at an exercise price of $0.40 per share, expiring five years after the issuance date. ASC 470-20 states that the proceeds from the issuance of debt with detachable stock warrants should be allocated between the debt and warrants on the basis of their relative fair market values. The debt discount will be amortized to interest expense over the two year term of these loans. We amortized $149,025 of the debt discount to interest expense in 2015. The warrants issued in connection with the convertible debentures are classified as warrant derivative liabilities because the warrants are entitled to certain rights in subsequent financings and the warrants contain “down-round protection” and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, (“ASC 815”). Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $1,182,439 to the total warrants out of the gross proceeds of $3,280,000. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first. The specific terms of the convertible debts and outstanding balances as of September 30, 2015 are listed in the tables below. Variable Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance as of September 30, 2015 Outstanding Balance as of November 10, 2015 Interest Rate Fees Fair value of conversion feature Prepayment Penalty Discount to VWAP Share reserve requirement December 4, 2013 12 months $ 223,000 $ 105,760 $ - 4 % $ 10,000 $ 59,903 20 % - February 2, 2015 12 months 100,000 - - * 4 % 5,000 62,219 19-33 % - February 2, 2015 12 months 120,000 - - * 4 % 5,000 74,663 19-33 % - February 22, 2015 six months 100,000 - - * 4 % - 61,597 19-33 % - February 25, 2015 12 months 112,500 - - * 8 % 4,000 312,847 19-33 % - March 4, 2015 12 months 52,500 - - * 4 % 2,500 53,213 19-38 % - March 6, 2015 12 months 236,250 - - * 2 % 33,900 212,918 19-35 % - March 17, 2015 24 months 50,000 - - * 4 % - 64,382 19-33 % - March 20, 2015 12 months 25,000 - - * 4 % - 25,077 19-33 % - March 26, 2015 12 months 150,000 - - * 6 % 2,000 164,501 19-37.5 % - March 27, 2015 12 months 52,500 - - * 4 % 2,500 57,502 19-38 % - March 27, 2015 12 months 100,000 - - * 8 % 8,000 154,359 19-38 % - April 1, 2015 12 months 100,000 138,046 - * 8 % - 155,793 25-35 % 40% of 10 days - April 20, 2015 12 months 81,250 - - * 4 % 6,563 117,679 20 % - April 28, 2015 12 months 54,050 - - * 9 % 4,050 35,143 20 % - May 12, 2015 12 months 107,764 130,394 130,501 * 4 % 7,763 145,527 20 % - May 20, 2015 12 months 100,000 135,000 135,000 4 % - 92,715 9.5-33 % 45% of 10 days 3,000,000 May 26, 2015 12 months 60,000 - - * 8 % 3,500 79,287 10-35 % - June 23, 2015 12 months 126,000 170,100 170,100 4 % 6,000 108,297 19-33 % 35% of 15 days 3,101,000 June 24, 2015 24 months 50,000 67,500 67,500 4 % - 54,511 19-33 % 35% of 10 days 1,000,000 July 2, 2015 12 months 52,500 70,875 70,875 4 % 2,500 54,297 19-33 % 35% of 15 days 1,500,000 July 2, 2015 12 months 52,500 67,500 67,500 4 % 2,500 54,297 19-33 % 35% of 15 days 1,000,000 $ 2,105,814 $ 845,175 $ 470,975 $ 105,776 $ 2,200,727 9,601,000 The loans above with outstanding balances of zero were outstanding as of December 31, 2014 and were paid off during the nine months ended September 30, 2015. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Fees Fair value of conversion feature Prepayment Penalty July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $218,000 1 10 % 2 $ 339,930 $ 1,360,416 20 % September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 642,271 20 % $ 3,280,000 $ 3,280,000 $ 328,000 $ 525,886 $ 2,002,687 1 The original issue discount is reflected in the first year. 2 The annual interest starts accruing in the second year. The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2015: Balance at December 31, 2014 $ 1,004,513 Issuance of convertible debt, face value 5,014,021 Discount on embedded conversion option at issuance (3,667,020 ) Discount on fair value of warrant liability at issuance (1,182,409 ) Repayment of convertible debt (2,107,065 ) Conversion of convertible debt into common stock (328,000 ) Payment of prepayment penalty (351,193 ) Accretion of interest and amortization of debt discount to interest expense through September 30, 2015 2,326,296 Balance at September 30, 2015 709,143 Less: current portion 296,818 Convertible debt, long-term portion $ 412,325 Other Notes On January 15, 2015 we signed a Merchant Agreement with a lender. Under the agreement we received $150,000 in exchange for rights to all customer receipts until the lender is paid $187,500, which was collected at the rate of $744 per business day. The payments were secured by essentially all tangible assets of the Company. $67,925 of the proceeds were used to pay off the outstanding balance of a previous loan from this lender. The Company paid $1,875 in fees in connection with this loan. The note was paid off in its entirety prior to September 30, 2015. On January 29, 2015 we signed a Merchant Agreement with a lender. Under the agreement we received $200,000 in exchange for rights to all customer receipts until the lender is paid $278,000, which was collected at the rate of $1,985 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $999 in fees in connection with this loan. The note was paid off in its entirety prior to September 30, 2015. On March 17, 2015 we signed a Merchant Agreement with a lender. Under the agreement we received $50,000 in exchange for rights to all customer receipts until the lender is paid $67,450, which was collected at the rate of $559 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $999 in fees in connection with this loan. The note was paid off in its entirety prior to September 30, 2015. On May 29, 2015 we signed a Merchant Agreement with a lender. Under the agreement we received $100,000 in exchange for rights to all customer receipts until the lender is paid $132,000, which was collected at the rate of $1,098 per business day. The payments were secured by essentially all tangible assets of the Company. The Company paid $3,999 in fees in connection with this loan. The note was paid off in its entirety prior to September 30, 2015. On August 28, 2015 we signed a Merchant Agreement with a lender. Under the agreement we received $300,000 in exchange for rights to all customer receipts until the lender is paid $384,000, to be collected at the rate of $2,560 per business day. The payments are not secured. On the closing date, $131,710 of the proceeds were used to pay off the outstanding balances of two existing Notes. The Company paid $6,000 in fees in connection with this loan. The outstanding balance is recorded as other debt on the balance sheet. During the nine months ended September 30, 2015 we signed two ninety day notes with an investor. Under the terms of the notes, the Company received a total of $500,000. The investor converted these loans in the Company’s offering on July 22, 2015. During the nine months ended September 30, 2015, the Company made payments of $537,641 in total on the non-convertible debt from non-related parties.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Deficit	7) Stockholders’ Deficit Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K As of September 30, 2015, there were no shares of Junior A, and Series A, B, C and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2014 for the pertinent disclosures of preferred stock. Stock Options and Warrants Our stockholders approved our amended 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,800,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards made under the Plan. Under the Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2015, options to acquire 1,720,750 shares were outstanding under the Plan with 79,250 shares available for future grant under the Plan. As of September 30, 2015, options to acquire 10,000 shares are outstanding under the 1999 Non-qualified Stock Option Plan. No additional options may be granted under the 1999 Non-qualified Stock Option Plan. On December 12, 2013 at the Company’s special meeting the shareholders approved the 2013 Equity Incentive Plan (the “ 2013 Plan In connection with the convertible debentures issued in July 2015 and September 2015, we also issued warrants to the lenders to purchase an aggregate 5,857,142 shares of the Common Stock, at an exercise price of $0.40 per share, expiring five years after the issuance date. We issued 1,171,427 warrants to the placement agent who assisted with these convertible debentures. The placement agent’s warrants have the same terms as the warrants issued to the lenders. The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average price Average price Total Shares per share Shares per share Shares Exercisable Balance outstanding, 01/01/14 1,771,708 $ 0.71 15,012,237 $ 0.57 16,783,945 16,611,528 Granted 1,675,500 0.30 8,903,000 0.38 10,578,500 Exercised - (4,208,658 ) 0.25 (4,208,658 ) Expired (10,000 ) 1.00 (524,468 ) 0.74 (534,468 ) Forfeited (30,958 ) 0.71 - - (30,958 ) Balance outstanding, 12/31/14 3,406,250 $ 0.51 19,182,111 $ 0.49 22,588,361 20,858,021 Granted - - 7,028,569 0.40 7,028,569 Exercised - - - - Expired (205,000 ) 1.00 (85,553 ) 0.50 (290,553 ) Forfeited - - - - - Balance outstanding, 9/30/2015 3,201,250 $ 0.48 26,125,127 $ 0.47 29,326,377 28,523,139 Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $0.30 - $0.39 1,675,500 9.0 $ 0.30 888,198 9.0 $ 0.30 0.40 - 0.49 311,000 7.6 0.40 311,000 7.6 0.40 0.50 - 0.59 251,250 6.9 0.50 251,250 6.9 0.50 0.60 - 0.69 467,500 4.2 0.60 451,564 4.2 0.60 1.00 - 1.25 496,000 2.2 1.00 496,000 2.2 1.00 $0.30 - $1.25 3,201,250 7.0 $ 0.48 2,398,012 6.3 $ 0.54 As of September 30, 2015, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was $165,176. The non-cash, stock-based compensation expense associated with the vesting of these options is expected to be $22,492 for the remainder of 2015, $83,440 in 2016 and $59,244 in 2017. Common Stock Issuances With respect to the convertible debenture for $223,000 signed by the Company on December 4, 2013, a lender, with the prior approval of the Company, chose to convert a portion of the outstanding note balance into shares of the Company’s common stock, and to extend the note for approximately 45 days after each conversion, as follows: On January 14, 2015 $25,000 was converted into 100,000 shares of the Company’s common stock. On February 25, 2015 $38,000 was converted into 140,741 shares of the Company’s common stock. On April 10, 2015 $35,000 was converted into 140,000 shares of the Company’s common stock. On May 29, 2015 $35,000 was converted into 140,000 shares of the Company’s common stock. On July 21, 2015 $20,000 was converted into 80,000 shares of the Company’s common stock. On August 13, 2015 $40,000 was converted into 160,000 shares of the Company’s common stock. On September 25, 2015 $30,000 was converted into 120,000 shares of the Company’s common stock. For each extension, the Company paid a fee of $13,000, $13,000, $10,000, and $8,000, respectively. This note was paid off in its entirety on November 5, 2015. During the nine months ended September 30, 2015, the Company issued 305,000 shares with a fair value of $80,050 for services. On August 14, 2015, the Company closed a Securities Exchange Agreement with Everest Investments Holdings of Warsaw, Poland under which Everest purchased 1,000,000 shares of the Company’s restricted Common Stock at a purchase price of $0.50/share. In exchange, the Company received 601,500 shares of Everest Investments (“Everest”), a publicly-traded company on the Main Market of the Warsaw Stock Exchange. The shares of Everest were valued at approximately $400,000 as of the closing date. With respect to the convertible debenture for $150,000 signed by the Company on June 4, 2014, a lender, with prior approval of the Company, chose to convert a portion of the outstanding note balance into shares of the Company’s common stock, and to extend the note for approximately 30 days after each conversion, as follows: On February 18, 2015 $25,000 was converted into 100,000 shares of the Company’s common stock. On March 18, 2015 $22,500 was converted into 90,000 shares of the Company’s common stock. On March 31, 2015 $27,500 was converted into 110,000 shares of the Company’s common stock. On April 17, 2015 $30,000 was converted into 120,000 shares of the Company’s common stock. For each extension, the Company paid a fee of $10,000, $0, $0, and $0. This note was paid off in its entirety on July 14, 2015. With respect to the convertible debenture for $75,000 signed by the Company on November 10, 2014, a lender, upon the request of the Company, on June 8, 2015 agreed to extend the conversion date of the note until July 20, 2015. The lender received 40,000 shares of the Company’s common stock in exchange for the extension. The Company recorded $10,000 to interest expense for this transaction. This note was paid off in its entirety on July 24, 2015.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	8) Subsequent Events On November 5, 2015 we paid off the balance $105,760 of the $223,000 convertible note from December 2013. On November 1, 2015 the Company entered into a revised lease agreement for its research and development space in Medford, MA. The revised agreement calls for the Company to receive an additional 833 square feet of lab and office space. The monthly lease of $5,585 will terminate on December 31, 2017. On October 28, 2015 the Company issued 200,000 shares of restricted common stock to an investor relations firm for services rendered. On October 2, 2015 we paid off the $100,000 convertible note from April 2, 2015. On October 1, 2015, the Company engaged an investor relations firmfor which the Company has agreed to pay 125,000 shares of restricted common stock to provide services for the six months from October 1, 2015 to March 31, 2016.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates To prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Concentrations	Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories. The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2015 and 2014. For the Three Months Ended September 30, 2015 2014 Top Five Customers 43 % 53 % Federal Agencies 2 % 1 % For the Nine Months Ended September 30, 2015 2014 Top Five Customers 34 % 31 % Federal Agencies 14 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Top Five Customers 61 % 86 % Federal Agencies 1 % 9 % Product Supply BIT Group, Inc. of California has been our sole contract manufacturer for our PCT NEP3229 and NEP2320 instrumentation. However, the Company has reached agreement for a Massachusetts-based contract manufacturer to assemble its future builds of the NEP2320 instrument, effective in early 2016.
Investment in Available-For-Sale Equity Securities	Investment in Available-For-Sale Equity Securities As of September 30, 2015, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”
Debt Issuance Costs	Debt Issuance Costs In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”, or ASU 2015-03. ASU 2015-03 amends current presentation guidance by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for interim and annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. Costs incurred in obtaining debt funding are currently deferred and amortized on an effective interest method over the terms of the loans. Amortization expense for 2015 and 2014 was $41,085 and $0 respectively, and has been classified with interest expense in the consolidated financial statements.
Computation of Loss per Share	Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss. The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2015 and 2014: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Numerator: Net loss $ (657,928 ) $ (959,050 ) $ (3,430,160 ) $ (3,321,892 ) Accrued dividend for Preferred Stock 1,711 (43,362 ) (21,768 ) (97,955 ) Deemed dividend on Series K Convertible Preferred Stock - - - (1,388,062 ) Net loss applicable to common shareholders $ (656,217 ) $ (1,002,412 ) $ (3,451,928 ) $ (4,807,909 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 20,737,827 15,238,466 19,771,323 13,648,795 Loss per common share - basic and diluted $ (0.03 ) $ (0.07 ) $ (0.17 ) $ (0.35 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. For the Nine Months Ended September 30, 2015 2014 Stock options 3,201,250 3,356,250 Convertible debt 26,015,029 4,091,151 Common stock warrants 26,125,127 17,895,717 Convertible preferred stock: Series D Convertible Preferred Stock 750,000 750,000 Series G Convertible Preferred Stock 865,700 865,700 Series H Convertible Preferred Stock 1,000,000 1,000,000 Series H2 Convertible Preferred Stock 2,100,000 - Series J Convertible Preferred Stock 3,546,000 3,548,000 Series K Convertible Preferred Stock 11,399,000 11,399,000 75,002,106 42,905,818
Accounting for Stock-Based Compensation Expense	Accounting for Stock-Based Compensation Expense We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.
Determining Fair Value of Stock Option Grants	Determining Fair Value of Stock Option Grants Valuation and Amortization Method - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period. Expected Term - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted. Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the award. Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term. Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense. The Company recognized stock-based compensation expense of $74,864 and $6,387 for the three months ended September 30, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Three Months Ended September 30, 2015 2014 Research and development $ 18,307 $ 1,749 Selling and marketing 13,310 1,391 General and administrative 43,247 3,247 Total stock-based compensation expense $ 74,864 $ 6,387 We recognized stock-based compensation expense of $185,370 and $46,771 for the nine months ended September 30, 2015 and 2014, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Nine Months Ended September 30, 2015 2014 Research and development $ 41,172 $ 19,602 Selling and marketing 27,386 13,296 General and administrative 116,812 13,873 Total stock-based compensation expense $ 185,370 $ 46,771
Fair Value of Financial Instruments	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.
Fair Value Measurements	Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015. Fair value measurements at September 30, 2015 using: September 30, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2015 (Level 1) (Level 2) (Level 3) Series D Preferred Stock Purchase Warrants $ 122,692 - - $ 122,692 Available-For-Sale Equity Securities 322,860 322,860 - - Convertible Debt Warrants 1,418,438 - - 1,418,438 Conversion Option Liabilities 2,227,330 - - 2,227,330 Total Derivatives $ 4,091,320 $ 322,860 $ - $ 3,768,460 January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities September 30, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ (37,183 ) $ - $ 122,692 Convertible Debt Warrants - 1,418,927 (489 ) - 1,418,438 Conversion Option Liabilities 590,341 4,143,051 (477,738 ) (2,028,324 ) 2,227,330 Total Derivatives $ 750,216 $ 5,561,978 $ (515,410 ) $ (2,028,324 ) $ 3,768,460 The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2014 Warrants revalued at September 30, 2015 Expected life (in months) 60.0 22.0 13.0 Expected volatility 104.5 % 116.0 % 117.5 % Risk-free interest rate 0.875 % 0.58 % 0.33 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.15 $ 0.11 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the year reflected on a per share common stock equivalent basis. Assumptions For the three months ended September 30, 2015 Warrants revalued at September 30, 2015 Expected life (in months) 60.0 60.0 Expected volatility 118.3 - 120.1 % 136.5 -138.2 % Risk-free interest rate 1.48-1.69 % 1.37 % Exercise price $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$.21 $ 0.20 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at September 30, 2015 Expected life (in months) 6-24 0-18 2-21 Expected volatility 104.2-153.8% 86.9%-142.2% 88.6-130.6% Risk-free interest rate 0.05-0.99% 0.01-0.72% 0.01-0.64% Exercise price $0.10-$0.35 $0.10-$0.25 $0.11-$0.25 Fair value per conversion option $0.09-$0.28 $0.07-$0.26 $0.08-$0.16

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Customer Concentration Risk Percentage	The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2015 and 2014. For the Three Months Ended September 30, 2015 2014 Top Five Customers 43 % 53 % Federal Agencies 2 % 1 % For the Nine Months Ended September 30, 2015 2014 Top Five Customers 34 % 31 % Federal Agencies 14 % 1 % The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2015 and December 31, 2014: September 30, 2015 December 31, 2014 Top Five Customers 61 % 86 % Federal Agencies 1 % 9 %
Summary of Computation of Loss per Share	The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2015 and 2014: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2015 2014 2015 2014 Numerator: Net loss $ (657,928 ) $ (959,050 ) $ (3,430,160 ) $ (3,321,892 ) Accrued dividend for Preferred Stock 1,711 (43,362 ) (21,768 ) (97,955 ) Deemed dividend on Series K Convertible Preferred Stock - - - (1,388,062 ) Net loss applicable to common shareholders $ (656,217 ) $ (1,002,412 ) $ (3,451,928 ) $ (4,807,909 ) Denominator for basic and diluted loss per share: Weighted average common stock shares outstanding 20,737,827 15,238,466 19,771,323 13,648,795 Loss per common share - basic and diluted $ (0.03 ) $ (0.07 ) $ (0.17 ) $ (0.35 )
Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms. For the Nine Months Ended September 30, 2015 2014 Stock options 3,201,250 3,356,250 Convertible debt 26,015,029 4,091,151 Common stock warrants 26,125,127 17,895,717 Convertible preferred stock: Series D Convertible Preferred Stock 750,000 750,000 Series G Convertible Preferred Stock 865,700 865,700 Series H Convertible Preferred Stock 1,000,000 1,000,000 Series H2 Convertible Preferred Stock 2,100,000 - Series J Convertible Preferred Stock 3,546,000 3,548,000 Series K Convertible Preferred Stock 11,399,000 11,399,000 75,002,106 42,905,818
Summary of Stock Based Compensation Expense	The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Three Months Ended September 30, 2015 2014 Research and development $ 18,307 $ 1,749 Selling and marketing 13,310 1,391 General and administrative 43,247 3,247 Total stock-based compensation expense $ 74,864 $ 6,387 The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations: For the Nine Months Ended September 30, 2015 2014 Research and development $ 41,172 $ 19,602 Selling and marketing 27,386 13,296 General and administrative 116,812 13,873 Total stock-based compensation expense $ 185,370 $ 46,771
Schedule of Liabilities Measured at Fair Value on Recurring Basis	The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015. Fair value measurements at September 30, 2015 using: September 30, Quoted prices in active markets Significant other observable inputs Significant unobservable inputs 2015 (Level 1) (Level 2) (Level 3) Series D Preferred Stock Purchase Warrants $ 122,692 - - $ 122,692 Available-For-Sale Equity Securities 322,860 322,860 - - Convertible Debt Warrants 1,418,438 - - 1,418,438 Conversion Option Liabilities 2,227,330 - - 2,227,330 Total Derivatives $ 4,091,320 $ 322,860 $ - $ 3,768,460 January 1, 2015 Issuance fair value Change in fair value Gain on extinguishment of derivative liabilities September 30, 2015 Series D Preferred Stock Purchase Warrants $ 159,875 $ - $ (37,183 ) $ - $ 122,692 Convertible Debt Warrants - 1,418,927 (489 ) - 1,418,438 Conversion Option Liabilities 590,341 4,143,051 (477,738 ) (2,028,324 ) 2,227,330 Total Derivatives $ 750,216 $ 5,561,978 $ (515,410 ) $ (2,028,324 ) $ 3,768,460
Schedule of Fair Value Assumptions	\ The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2014 Warrants revalued at September 30, 2015 Expected life (in months) 60.0 22.0 13.0 Expected volatility 104.5 % 116.0 % 117.5 % Risk-free interest rate 0.875 % 0.58 % 0.33 % Exercise price $ 0.81 $ 0.25 $ 0.25 Fair value per warrant $ 0.54 $ 0.15 $ 0.11 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the year reflected on a per share common stock equivalent basis. Assumptions For the three months ended September 30, 2015 Warrants revalued at September 30, 2015 Expected life (in months) 60.0 60.0 Expected volatility 118.3 - 120.1 % 136.5 -138.2 % Risk-free interest rate 1.48-1.69 % 1.37 % Exercise price $ 0.40 $ 0.40 Fair value per warrant $ 0.19-$.21 $ 0.20 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at September 30, 2015 Expected life (in months) 6-24 0-18 2-21 Expected volatility 104.2-153.8% 86.9%-142.2% 88.6-130.6% Risk-free interest rate 0.05-0.99% 0.01-0.72% 0.01-0.64% Exercise price $0.10-$0.35 $0.10-$0.25 $0.11-$0.25 Fair value per conversion option $0.09-$0.28 $0.07-$0.26 $0.08-$0.16

Convertible Debt and Other De17

Convertible Debt and Other Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible debts and outstanding balances as of September 30, 2015 are listed in the tables below. Variable Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance as of September 30, 2015 Outstanding Balance as of November 10, 2015 Interest Rate Fees Fair value of conversion feature Prepayment Penalty Discount to VWAP Share reserve requirement December 4, 2013 12 months $ 223,000 $ 105,760 $ - 4 % $ 10,000 $ 59,903 20 % - February 2, 2015 12 months 100,000 - - * 4 % 5,000 62,219 19-33 % - February 2, 2015 12 months 120,000 - - * 4 % 5,000 74,663 19-33 % - February 22, 2015 six months 100,000 - - * 4 % - 61,597 19-33 % - February 25, 2015 12 months 112,500 - - * 8 % 4,000 312,847 19-33 % - March 4, 2015 12 months 52,500 - - * 4 % 2,500 53,213 19-38 % - March 6, 2015 12 months 236,250 - - * 2 % 33,900 212,918 19-35 % - March 17, 2015 24 months 50,000 - - * 4 % - 64,382 19-33 % - March 20, 2015 12 months 25,000 - - * 4 % - 25,077 19-33 % - March 26, 2015 12 months 150,000 - - * 6 % 2,000 164,501 19-37.5 % - March 27, 2015 12 months 52,500 - - * 4 % 2,500 57,502 19-38 % - March 27, 2015 12 months 100,000 - - * 8 % 8,000 154,359 19-38 % - April 1, 2015 12 months 100,000 138,046 - * 8 % - 155,793 25-35 % 40% of 10 days - April 20, 2015 12 months 81,250 - - * 4 % 6,563 117,679 20 % - April 28, 2015 12 months 54,050 - - * 9 % 4,050 35,143 20 % - May 12, 2015 12 months 107,764 130,394 130,501 * 4 % 7,763 145,527 20 % - May 20, 2015 12 months 100,000 135,000 135,000 4 % - 92,715 9.5-33 % 45% of 10 days 3,000,000 May 26, 2015 12 months 60,000 - - * 8 % 3,500 79,287 10-35 % - June 23, 2015 12 months 126,000 170,100 170,100 4 % 6,000 108,297 19-33 % 35% of 15 days 3,101,000 June 24, 2015 24 months 50,000 67,500 67,500 4 % - 54,511 19-33 % 35% of 10 days 1,000,000 July 2, 2015 12 months 52,500 70,875 70,875 4 % 2,500 54,297 19-33 % 35% of 15 days 1,500,000 July 2, 2015 12 months 52,500 67,500 67,500 4 % 2,500 54,297 19-33 % 35% of 15 days 1,000,000 $ 2,105,814 $ 845,175 $ 470,975 $ 105,776 $ 2,200,727 9,601,000 The loans above with outstanding balances of zero were outstanding as of December 31, 2014 and were paid off during the nine months ended September 30, 2015. Fixed Rate Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Fees Fair value of conversion feature Prepayment Penalty July 22, 2015 24 months $ 2,180,000 $ 2,180,000 $218,000 1 10 % 2 $ 339,930 $ 1,360,416 20 % September 25, 2015 24 months 1,100,000 1,100,000 110,000 1 10 % 2 185,956 642,271 20 % $ 3,280,000 $ 3,280,000 $ 328,000 $ 525,886 $ 2,002,687 1 The original issue discount is reflected in the first year. 2 The annual interest starts accruing in the second year.
Summary of Changes in Convertible Debt, Net of Unamortized Discount	The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2015: Balance at December 31, 2014 $ 1,004,513 Issuance of convertible debt, face value 5,014,021 Discount on embedded conversion option at issuance (3,667,020 ) Discount on fair value of warrant liability at issuance (1,182,409 ) Repayment of convertible debt (2,107,065 ) Conversion of convertible debt into common stock (328,000 ) Payment of prepayment penalty (351,193 ) Accretion of interest and amortization of debt discount to interest expense through September 30, 2015 2,326,296 Balance at September 30, 2015 709,143 Less: current portion 296,818 Convertible debt, long-term portion $ 412,325

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Weighted Weighted Average price Average price Total Shares per share Shares per share Shares Exercisable Balance outstanding, 01/01/14 1,771,708 $ 0.71 15,012,237 $ 0.57 16,783,945 16,611,528 Granted 1,675,500 0.30 8,903,000 0.38 10,578,500 Exercised - (4,208,658 ) 0.25 (4,208,658 ) Expired (10,000 ) 1.00 (524,468 ) 0.74 (534,468 ) Forfeited (30,958 ) 0.71 - - (30,958 ) Balance outstanding, 12/31/14 3,406,250 $ 0.51 19,182,111 $ 0.49 22,588,361 20,858,021 Granted - - 7,028,569 0.40 7,028,569 Exercised - - - - Expired (205,000 ) 1.00 (85,553 ) 0.50 (290,553 ) Forfeited - - - - - Balance outstanding, 9/30/2015 3,201,250 $ 0.48 26,125,127 $ 0.47 29,326,377 28,523,139
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $0.30 - $0.39 1,675,500 9.0 $ 0.30 888,198 9.0 $ 0.30 0.40 - 0.49 311,000 7.6 0.40 311,000 7.6 0.40 0.50 - 0.59 251,250 6.9 0.50 251,250 6.9 0.50 0.60 - 0.69 467,500 4.2 0.60 451,564 4.2 0.60 1.00 - 1.25 496,000 2.2 1.00 496,000 2.2 1.00 $0.30 - $1.25 3,201,250 7.0 $ 0.48 2,398,012 6.3 $ 0.54

Business Overview, Liquidity 19

Business Overview, Liquidity and Management Plans (Details Narrative)	9 Months Ended
	Sep. 30, 2015lb
Pounds per square inch	35,000
PBI Europe [Member]
Percentage of ownership interest	49.00%
Investment Bank [Member]
Percentage of ownership interest	51.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative)	9 Months Ended
	Sep. 30, 2015USD ($)
Going Concern
Net proceeds from additional convertible and non-convertible debt	$ 5,952,053

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Aug. 14, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Forfeiture rate percentage				5.00%
Stock-based compensation expense		$ 74,864	$ 6,387	$ 185,370	$ 46,771
Debt amortization expense				$ 41,085	$ 0
Everest Investments Holding [Member]
Sale of stock number of shares recevied	601,500			601,500
Fair value of investment		$ 323,860		$ 323,860
Closing price per share		$ 0.54		$ 0.54

Summary of Significant Accoun22

Summary of Significant Accounting Policies - Summary of Customer Concentration Risk Percentage (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Top Five Customers [Member] | Sales Revenue, Net [Member]
Concentration as a percentage	43.00%	53.00%	34.00%	31.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration as a percentage			61.00%		86.00%
Federal Agencies [Member] | Sales Revenue, Net [Member]
Concentration as a percentage	2.00%	1.00%	14.00%	1.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration as a percentage			1.00%		9.00%

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Summary of Computation of Loss per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accounting Policies [Abstract]
Net loss	$ (657,928)	$ (959,050)	$ (3,430,160)	$ (3,321,892)
Accrued dividend for Preferred Stock	$ 1,711	$ (43,362)	$ (21,768)	(97,955)
Deemed dividend on Series K convertible preferred stock				(1,388,062)
Net loss applicable to common shareholders	$ (656,217)	$ (1,002,412)	$ (3,451,928)	$ (4,807,909)
Weighted average common stock shares outstanding	20,737,827	15,238,466	19,771,323	13,648,795
Loss per common share - basic and diluted	$ (0.03)	$ (0.07)	$ (0.17)	$ (0.35)

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Computation of Earnings per Share (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Total potentially dilutive shares	75,002,106	42,905,818
2005 Equity Incentive [Member]
Total potentially dilutive shares	3,201,250	3,356,250
Convertible Debt [Member]
Total potentially dilutive shares	26,015,029	4,091,151
Common Stock Warrants [Member]
Total potentially dilutive shares	26,125,127	17,895,717
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	750,000	750,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	865,700	865,700
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	1,000,000	1,000,000
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	2,100,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	3,546,000	3,548,000
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	11,399,000	11,399,000

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Summary of Stock Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Stock-based compensation expense	$ 74,864	$ 6,387	$ 185,370	$ 46,771
Research and Development [Member]
Stock-based compensation expense	18,307	1,749	41,172	19,602
Selling and Marketing [Member]
Stock-based compensation expense	13,310	1,391	27,386	13,296
General and Administrative [Member]
Stock-based compensation expense	$ 43,247	$ 3,247	$ 116,812	$ 13,873

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value on Recurring Basis (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Fair value of derivative liability	$ 4,091,320
Balance	750,216
Issuance fair value	5,561,978
Change in Fair Value	(515,410)
Gain on extinguishment of derivative liabilities	(2,028,324)
Balance	3,768,460
Quoted Prices in Active Markets [Member]
Fair value of derivative liability	$ 322,860
Significant Other Observable Inputs [Member]
Fair value of derivative liability
Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 3,768,460
Series D Preferred Stock Purchase Warrants [Member]
Fair value of derivative liability	122,692
Balance	$ 159,875
Issuance fair value
Change in Fair Value	$ (37,183)
Gain on extinguishment of derivative liabilities
Balance	$ 122,692
Series D Preferred Stock Purchase Warrants [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 122,692
Available-For-Sale Equity Securities [Member]
Fair value of derivative liability	322,860
Balance	322,860
Available-For-Sale Equity Securities [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability	$ 322,860
Available-For-Sale Equity Securities [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Available-For-Sale Equity Securities [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability
Convertible Debt Warrants [Member]
Fair value of derivative liability	$ 1,418,438
Balance
Issuance fair value	$ 1,418,927
Change in Fair Value	$ (489)
Gain on extinguishment of derivative liabilities
Balance	$ 1,418,438
Convertible Debt Warrants [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability
Convertible Debt Warrants [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Convertible Debt Warrants [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 1,418,438
Conversion Option Liabilities [Member]
Fair value of derivative liability	2,227,330
Balance	590,341
Issuance fair value	4,143,051
Change in Fair Value	(477,738)
Gain on extinguishment of derivative liabilities	(2,028,324)
Balance	$ 2,227,330
Conversion Option Liabilities [Member] | Quoted Prices in Active Markets [Member]
Fair value of derivative liability
Conversion Option Liabilities [Member] | Significant Other Observable Inputs [Member]
Fair value of derivative liability
Conversion Option Liabilities [Member] | Significant Unobservable Inputs [Member]
Fair value of derivative liability	$ 2,227,330

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Fair Value Assumptions (Details) - $ / shares	Sep. 30, 2015	Dec. 31, 2014	Nov. 10, 2011	Sep. 30, 2015	Sep. 30, 2015
Expected life (in months)			60 months	6 months
Expected volatility			104.50%
Risk-free interest rate			0.875%
Exercise price	$ 0.40		$ 0.81	$ 0.40	$ 0.40
Fair value per share			$ 0.54
Minimum [Member]
Expected volatility				118.30%
Risk-free interest rate				1.48%
Fair value per share	0.19			$ 0.19	0.19
Maximum [Member]
Expected volatility				120.10%
Risk-free interest rate				1.69%
Fair value per share	$ 0.21			$ 0.21	0.21
Warrants Revalued at December 31, 2014 [Member]
Expected life (in months)		22 months
Expected volatility		116.00%
Risk-free interest rate		0.58%
Exercise price		$ 0.25
Fair value per share		$ 0.15
Warrants Revalued at September 30, 2015 [Member]
Expected life (in months)	16 months
Expected volatility	117.50%
Risk-free interest rate	0.33%
Exercise price	$ .25			.25	.25
Fair value per share	.11			.11	$ .11
Issuance Fair Value [Member] | Minimum [Member]
Expected life (in months)					6 months
Expected volatility					104.20%
Risk-free interest rate					0.05%
Exercise price	.10			.10	$ .10
Fair value per share	.09			.09	$ .09
Issuance Fair Value [Member] | Maximum [Member]
Expected life (in months)					24 months
Expected volatility					153.80%
Risk-free interest rate					0.99%
Exercise price	.35			.35	$ .35
Fair value per share	.28			.28	$ .28
Settlement Fair Value [Member] | Minimum [Member]
Expected life (in months)					0 years
Expected volatility					86.90%
Risk-free interest rate					0.01%
Exercise price	0.10			0.10	$ 0.10
Fair value per share	0.07			0.07	$ 0.07
Settlement Fair Value [Member] | Maximum [Member]
Expected life (in months)					18 months
Expected volatility					142.20%
Risk-free interest rate					0.72%
Exercise price	0.25			0.25	$ 0.25
Fair value per share	0.26			0.26	$ 0.26
Conversion options revalued at June 30, 2015 [Member] | Minimum [Member]
Expected life (in months)					2 months
Expected volatility					88.60%
Risk-free interest rate					0.01%
Exercise price	.11			.11	$ .11
Fair value per share	.08			.08	$ .08
Conversion options revalued at June 30, 2015 [Member] | Maximum [Member]
Expected life (in months)					21 months
Expected volatility					130.60%
Risk-free interest rate					0.64%
Exercise price	0.25			0.25	$ 0.25
Fair value per share	0.16			$ 0.16	0.16
Warrants Revalued at September 30, 2015 [Member]
Expected life (in months)				6 months
Risk-free interest rate				1.37%
Exercise price	0.40			$ 0.40	0.40
Fair value per share	$ 0.20			$ 0.20	$ 0.20
Warrants Revalued at September 30, 2015 [Member] | Minimum [Member]
Expected volatility				136.50%
Warrants Revalued at September 30, 2015 [Member] | Maximum [Member]
Expected volatility				138.20%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	1 Months Ended		9 Months Ended
	Sep. 30, 2014USD ($)ft²	Nov. 30, 2007USD ($)ft²	Sep. 30, 2015USD ($)ft²	Sep. 30, 2014USD ($)ft²
Lease agreement description		In November 2007, we signed a lease agreement commencing in February 2008 pursuant to which we lease approximately 5,500 square feet of office space. We extended the lease term until December 31, 2015 with a monthly payment of $4,800.
Area of lease | ft²	855	5,500		855
Extended lease term	Dec. 31, 2017	Dec. 31, 2015
Rental expenses	$ 3,094	$ 4,800	$ 73,775	$ 43,200
Grand received			$ 1,050,000
November 1, 2015 [Member]
Area of lease | ft²			833
Rental expenses			$ 5,385

Convertible Debt and Other De29

Convertible Debt and Other Debt (Details Narrative) - USD ($)

Aug. 28, 2015

May. 29, 2015

Mar. 17, 2015

Jan. 29, 2015

Jan. 15, 2015

Sep. 30, 2015

Sep. 30, 2014

Apr. 17, 2015

Apr. 10, 2015

Mar. 31, 2015

Mar. 27, 2015

Mar. 18, 2015

Feb. 25, 2015

Feb. 18, 2015

Jan. 14, 2015

Amortized debt discount

$ 2,367,381

$ 611,919

Fair value of warrants

(1,182,409)

Convertible debenture face amount

5,014,021

Initial payment by lender as per the agreement

500,000

Debenture fee

$ 8,000

680,264

$ 0

$ 10,000

$ 0

$ 0

$ 13,000

$ 10,000

$ 13,000

Proceeds form issuance of note payable

5,952,053

Payments on non-convertible debt

$ (537,641)

$ (267,377)

Convertible Debenture [Member]

Convertible debenture interest rate minimum

4.00%

Convertible debenture interest rate maximum

10.00%

Debt conversion threshold number of trading days

180 days

Convertible Debenture [Member] | Minimum [Member]

Convertible debenture term

12 months

Debt prepayment penalties percentage

19.00%

Convertible Debenture [Member] | Maximum [Member]

Convertible debenture term

24 months

Debt prepayment penalties percentage

38.00%

Senior Secured Convertible Debentures [Member] | July 2015 and September 2015 [Member]

Convertible debenture term

2 years

Issuance of warrants to purchase of common stock shares

5,857,142

Warrants exercise price per share

$ 0.40

Warrants term

5 years

Amortized debt discount

$ 149,025

Fair value of warrants

1,182,439

Gross proceeds from warrants

$ 3,280,000

Other Notes Jan 15, 2015 [Member]

Convertible debenture face amount

$ 150,000

Initial payment by lender as per the agreement

187,500

Debenture fee

1,875

Pay off outstanding balance of previous loan from lender

67,925

Debt payment per business day

$ 744

Other Notes Jan 29, 2015 [Member]

Convertible debenture face amount

$ 200,000

Initial payment by lender as per the agreement

278,000

Debenture fee

999

Debt payment per business day

$ 1,985

Other Notes Mar 17, 2015 [Member]

Convertible debenture face amount

$ 50,000

Initial payment by lender as per the agreement

67,450

Debenture fee

$ 999

Debt payment per business day

$ 559

Other Notes May 29, 2015 [Member]

Convertible debenture face amount

100,000

Initial payment by lender as per the agreement

132,000

Debenture fee

3,999

Debt payment per business day

$ 1,098

Other Notes August 28, 2015 [Member]

Convertible debenture face amount

$ 300,000

Initial payment by lender as per the agreement

384,000

Debenture fee

6,000

Debt payment per business day

2,560

Proceeds form issuance of note payable

$ 131,710

Convertible Debt and Other De30

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)

9 Months Ended

Sep. 30, 2015

May. 29, 2015

May. 12, 2015

Apr. 17, 2015

Apr. 10, 2015

Mar. 31, 2015

Mar. 18, 2015

Feb. 25, 2015

Feb. 18, 2015

Jan. 14, 2015

Nov. 10, 2014

Jun. 04, 2014

Dec. 04, 2013

Loan Amount

$ 5,014,021

Outstanding Balance

3,963,523

$ 75,000

$ 150,000

$ 223,000

Fees

680,264

$ 8,000

$ 0

$ 10,000

$ 0

$ 0

$ 13,000

$ 10,000

$ 13,000

Variable Rate Convertible Notes [Member]

Loan Amount

2,105,814

Outstanding Balance

845,175

Fees

105,776

Fair value of conversion feature

$ 2,200,727

Share reserve requirement

9,601,000

Variable Rate Convertible Notes [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 470,975

Variable Rate Convertible Notes [Member] | Convertible Debt One [Member]

Inception Date

Dec. 4, 2013

Term

12 months

Loan Amount

$ 223,000

Outstanding Balance

$ 105,760

Interest Rate

4.00%

Fees

$ 10,000

Fair value of conversion feature

$ 59,903

Prepayment Penalty

20.00%

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Two [Member]

Inception Date

Feb. 2, 2015

Term

12 months

Loan Amount

$ 100,000

Outstanding Balance

Interest Rate

4.00%

Fees

$ 5,000

Fair value of conversion feature

$ 62,219

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Two [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Two [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Three [Member]

Inception Date

Feb. 2, 2015

Term

12 months

Loan Amount

$ 120,000

Outstanding Balance

Interest Rate

4.00%

Fees

$ 5,000

Fair value of conversion feature

$ 74,663

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Three [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Three [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Four [Member]

Inception Date

Feb. 22, 2015

Term

6 months

Loan Amount

$ 100,000

Outstanding Balance

Interest Rate

4.00%

Fees

Fair value of conversion feature

$ 61,597

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Four [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Four [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Five [Member]

Inception Date

Feb. 25, 2015

Term

12 months

Loan Amount

$ 112,500

Outstanding Balance

Interest Rate

8.00%

Fees

$ 4,000

Fair value of conversion feature

$ 312,847

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Five [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Five [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member]

Inception Date

Mar. 4, 2015

Term

12 months

Loan Amount

$ 52,500

Outstanding Balance

Interest Rate

4.00%

Fees

$ 2,500

Fair value of conversion feature

$ 53,213

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 130,501

Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Six [Member] | Maximum [Member]

Prepayment Penalty

38.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Seven [Member]

Inception Date

Mar. 6, 2015

Term

12 months

Loan Amount

$ 236,250

Outstanding Balance

Interest Rate

2.00%

Fees

$ 33,900

Fair value of conversion feature

$ 212,918

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Seven [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Seven [Member] | Maximum [Member]

Prepayment Penalty

35.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Eight [Member]

Inception Date

Mar. 17, 2015

Term

24 months

Loan Amount

$ 50,000

Outstanding Balance

Interest Rate

4.00%

Fees

Fair value of conversion feature

$ 64,382

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Eight [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Eight [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Nine [Member]

Inception Date

Mar. 20, 2015

Term

12 months

Loan Amount

$ 25,000

Outstanding Balance

Interest Rate

4.00%

Fees

Fair value of conversion feature

$ 25,077

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Nine [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Nine [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Ten [Member]

Inception Date

Mar. 26, 2015

Term

12 months

Loan Amount

$ 150,000

Outstanding Balance

Interest Rate

6.00%

Fees

$ 2,000

Fair value of conversion feature

$ 164,501

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Ten [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Ten [Member] | Maximum [Member]

Prepayment Penalty

37.50%

Variable Rate Convertible Notes [Member] | Convertible Debt Eleven [Member]

Inception Date

Mar. 27, 2015

Term

12 months

Loan Amount

$ 52,500

Outstanding Balance

Interest Rate

4.00%

Fees

$ 2,500

Fair value of conversion feature

$ 57,502

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Eleven [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Eleven [Member] | Maximum [Member]

Prepayment Penalty

38.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member]

Inception Date

Mar. 27, 2015

Term

12 months

Loan Amount

$ 100,000

Outstanding Balance

Interest Rate

8.00%

Fees

$ 8,000

Fair value of conversion feature

$ 154,359

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Tweleve [Member] | Maximum [Member]

Prepayment Penalty

38.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member]

Inception Date

Apr. 1, 2015

Term

12 months

Loan Amount

$ 100,000

Outstanding Balance

$ 100,000

Interest Rate

8.00%

Fees

Fair value of conversion feature

$ 155,793

Discount to VWAP

40% of 10 days

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member] | Minimum [Member]

Prepayment Penalty

25.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Thirteen [Member] | Maximum [Member]

Prepayment Penalty

35.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Fourteen [Member]

Inception Date

Apr. 20, 2015

Term

12 months

Loan Amount

$ 81,250

Outstanding Balance

Interest Rate

4.00%

Fees

$ 6,563

Fair value of conversion feature

$ 117,679

Prepayment Penalty

20.00%

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Fifteen [Member]

Inception Date

Apr. 28, 2015

Term

12 months

Loan Amount

$ 54,050

Outstanding Balance

Interest Rate

9.00%

Fees

$ 4,050

Fair value of conversion feature

$ 35,143

Prepayment Penalty

20.00%

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Sixteen [Member]

Inception Date

May 12, 2015

Term

12 months

Loan Amount

$ 107,764

Outstanding Balance

$ 130,394

Interest Rate

4.00%

Fees

$ 7,763

Fair value of conversion feature

$ 145,527

Prepayment Penalty

20.00%

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member]

Inception Date

May 20, 2015

Term

12 months

Loan Amount

$ 100,000

Outstanding Balance

$ 135,000

Interest Rate

4.00%

Fees

Fair value of conversion feature

$ 92,715

Discount to VWAP

45% of 10 days

Share reserve requirement

3,000,000

Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 135,000

Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member] | Minimum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Seventeen [Member] | Maximum [Member]

Prepayment Penalty

9.50%

Variable Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member]

Inception Date

May 26, 2015

Term

12 months

Loan Amount

$ 60,000

Outstanding Balance

Interest Rate

8.00%

Fees

$ 3,500

Fair value of conversion feature

$ 79,287

Share reserve requirement

Variable Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member] | Minimum [Member]

Prepayment Penalty

35.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Eighteen [Member] | Maximum [Member]

Prepayment Penalty

10.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member]

Inception Date

Jun. 23, 2015

Term

12 months

Loan Amount

$ 126,000

Outstanding Balance

$ 170,100

Interest Rate

4.00%

Fees

$ 6,000

Fair value of conversion feature

$ 108,297

Discount to VWAP

35% of 15 days

Share reserve requirement

3,101,000

Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 170,100

Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member] | Minimum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Nineteen [Member] | Maximum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member]

Inception Date

Jun. 24, 2015

Term

24 months

Loan Amount

$ 50,000

Outstanding Balance

$ 67,500

Interest Rate

4.00%

Fees

Fair value of conversion feature

$ 54,511

Discount to VWAP

35% of 10 days

Share reserve requirement

1,000,000

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 67,500

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member]

Inception Date

Jul. 2, 2015

Term

12 months

Loan Amount

$ 52,500

Outstanding Balance

$ 70,875

Interest Rate

4.00%

Fees

$ 2,500

Fair value of conversion feature

$ 54,297

Discount to VWAP

35% of 15 days

Share reserve requirement

1,500,000

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 70,875

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty One [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member]

Inception Date

Jul. 2, 2015

Term

12 months

Loan Amount

$ 52,500

Outstanding Balance

$ 67,500

Interest Rate

4.00%

Fees

$ 2,500

Fair value of conversion feature

$ 54,297

Discount to VWAP

35% of 15 days

Share reserve requirement

1,000,000

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member] | November 10, 2015 [Member]

Outstanding Balance

$ 67,500

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member] | Minimum [Member]

Prepayment Penalty

19.00%

Variable Rate Convertible Notes [Member] | Convertible Debt Twenty Two [Member] | Maximum [Member]

Prepayment Penalty

33.00%

Fixed Rate Convertible Notes [Member]

Loan Amount

$ 3,280,000

Outstanding Balance

3,280,000

OID

328,000

Fees

525,886

Fair value of conversion feature

$ 2,002,687

Fixed Rate Convertible Notes [Member] | Convertible Debt One [Member]

Inception Date

Jul. 22, 2015

Term

24 months

Loan Amount

$ 2,180,000

Outstanding Balance

2,180,000

OID

[1]

$ 218,000

Interest Rate

[2]

10.00%

Fees

$ 339,930

Fair value of conversion feature

$ 1,360,416

Prepayment Penalty

20.00%

Fixed Rate Convertible Notes [Member] | Convertible Debt Two [Member]

Inception Date

Sep. 25, 2015

Term

24 months

Loan Amount

$ 1,100,000

Outstanding Balance

1,100,000

OID

[1]

$ 110,000

Interest Rate

[2]

10.00%

Fees

$ 185,956

Fair value of conversion feature

$ 642,271

Prepayment Penalty

20.00%

[1]

The original issue discount is reflected in the first year.

[2]

The annual interest starts accruing in the second year.

Convertible Debt and Other De31

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discount (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Debt Disclosure [Abstract]
Balance at December 31, 2014	$ 1,004,513
Issuance of convertible debt, face value	5,014,021
Discount on embedded conversion option at issuance	(3,667,020)
Discount on fair value of warrant liability at issuance	(1,182,409)
Repayment of convertible debt	$ (2,107,065)	$ (303,100)
Conversion of convertible debt into common stock	(328,000)
Payment of prepayment penalty	$ (351,193)
Accretion of interest and amortization of debt discount to interest expense through September 30, 2015	2,326,296
Balance at September 30, 2015	709,143
Less: current portion	296,818		$ 1,004,513
Convertible debt, long-term portion	$ 412,325

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Sep. 25, 2015	Aug. 14, 2015	Aug. 13, 2015	Jul. 21, 2015	Jun. 24, 2015	May. 29, 2015	Apr. 17, 2015	Apr. 10, 2015	Mar. 31, 2015	Mar. 18, 2015	Feb. 25, 2015	Feb. 18, 2015	Jan. 14, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Nov. 10, 2014	Jun. 04, 2014	Dec. 31, 2013	Dec. 12, 2013	Dec. 04, 2013
Convertible preferred stock, authorized														1,000,000		1,000,000
Convertible preferred stock, par value														$ 0.01		$ 0.01
Convertible preferred stock, shares issued														1,000,000		1,000,000
Common stock, shares outstanding under the plan														29,326,377		29,326,377		22,588,451			16,784,035
Estimated fair value of unvested stock options																$ 165,176
Convertible debt amount														$ 3,963,523		3,963,523			$ 75,000	$ 150,000			$ 223,000
Stock based compensation expenses														74,864	$ 6,387	$ 185,370	$ 46,771
Conversion of convertible debt	$ 30,000		$ 40,000	$ 20,000		$ 35,000	$ 30,000	$ 35,000	$ 27,500	$ 22,500	$ 38,000	$ 25,000	$ 25,000
Conversion of convertible debt, shares	120,000		160,000	80,000	40,000	140,000	120,000	140,000	110,000	90,000	140,741	100,000	100,000
Number of common stock shares issued																305,000
Number of common stock value issued																$ 80,050
Debenture fee						$ 8,000	$ 0	$ 10,000	$ 0	$ 0	$ 13,000	$ 10,000	$ 13,000	680,264		680,264
Interest expense					$ 10,000									$ 1,584,830	$ 179,942	$ 2,831,106	$ 658,255
Everest Investments Holding [Member]
Restricted stock price per share														$ 0.54		$ 0.54
Sale of stock number of shares recevied		601,500														601,500
Sale of stock value of shares recevied		$ 400,000
Remainder of 2015 [Member]
Stock based compensation expenses																$ 22,492
2016 [Member]
Stock based compensation expenses																83,440
2017 [Member]
Stock based compensation expenses																$ 59,244
Convertible Debenture [Member] | July 2015 and September 2015 [Member] | Placement Agent [Member]
Issuance of warrants to purchase of common stock shares																5,857,142
Warrants exercise price per share														$ 0.40		$ 0.40
Warrants term																5 years
Number of Warrants issued during period																1,171,427
2005 Equity Incentive [Member]
Common stock reserved for stock option plan														1,800,000		1,800,000
Common stock, shares outstanding under the plan														1,720,750		1,720,750
Common stock, shares available for future grant														79,250		79,250
1999 Non-qualified Stock Option Plan [Member]
Common stock, shares outstanding under the plan														10,000		10,000
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																						3,000,000
Common stock, shares available for future grant																						1,675,500
Restricted Stock Units [Member] | Everest Investments Holding [Member]
Number of restricted common stock purchased		1,000,000
Restricted stock price per share		$ 0.50
Series A Junior Participating Preferred Stock [Member]
Number of stock designated														20,000		20,000
Series A Convertible Preferred Stock [Member]
Number of stock designated														313,960		313,960
Series B Convertible Preferred Stock [Member]
Number of stock designated														279,256		279,256
Series C Convertible Preferred Stock [Member]
Number of stock designated														88,098		88,098
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, authorized														850		850		850
Convertible preferred stock, par value														$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued														300		300		300
Convertible preferred stock, shares outstanding														300		300		300
Number of stock designated														850		850
Series E Convertible Preferred Stock [Member]
Number of stock designated														500		500
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, authorized														240,000		240,000		240,000
Convertible preferred stock, par value														$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued														86,570		86,570		86,570
Convertible preferred stock, shares outstanding														86,570		86,570		86,570
Number of stock designated														240,000		240,000
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, authorized														10,000		10,000		10,000
Convertible preferred stock, par value														$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued														10,000		10,000		10,000
Convertible preferred stock, shares outstanding														10,000		10,000		10,000
Number of stock designated														10,000		10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, authorized														21		21		21
Convertible preferred stock, par value														$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued														21		21		21
Convertible preferred stock, shares outstanding														21		21		21
Number of stock designated														21		21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, authorized														6,250		6,250		6,250
Convertible preferred stock, par value														$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued														3,546		3,546		3,546
Convertible preferred stock, shares outstanding														3,546		3,546		3,546
Number of stock designated														6,250		6,250
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, authorized														15,000		15,000		15,000
Convertible preferred stock, par value														$ 0.01		$ 0.01		$ 0.01
Convertible preferred stock, shares issued														11,416		11,416		11,416
Convertible preferred stock, shares outstanding														11,416		11,416		11,416
Number of stock designated														15,000		15,000

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Shares, Beginning balance	22,588,451	16,784,035
Shares, granted	7,028,649	10,578,500
Shares, exercised		(4,208,658)
Shares, expired	(290,553)	(534,468)
Shares, forfeited		(30,958)
Shares, Ending balance	29,326,377	22,588,451
Exercisable, Beginning balance	20,858,021	16,611,528
Exercisable, Ending balance	28,523,139	20,858,021
Stock Option [Member]
Shares, Beginning balance	3,406,250	1,771,708
Shares, granted		1,675,500
Shares, exercised
Shares, expired	(205,000)	(10,000)
Shares, forfeited		(30,958)
Shares, Ending balance	3,201,250	3,406,250
Weighted average price per share, Beginning balance	$ 0.51	$ 0.71
Weighted average price per share, granted		$ 0.30
Weighted average price per share, exercised
Weighted average price per share, expired	$ 1	$ 1
Weighted average price per share, forfeited		0.71
Weighted average price per share, Ending balance	$ 0.48	$ 0.51
Warrants [Member]
Shares, Beginning balance	19,182,111	15,012,327
Shares, granted	7,028,649	8,903,000
Shares, exercised		(4,208,658)
Shares, expired	(85,553)	(524,468)
Shares, forfeited
Shares, Ending balance	26,125,127	19,182,111
Weighted average price per share, Beginning balance	$ 0.49	$ 0.57
Weighted average price per share, granted	$ 0.40	0.38
Weighted average price per share, exercised		0.25
Weighted average price per share, expired	$ 0.50	$ .74
Weighted average price per share, forfeited
Weighted average price per share, Ending balance	$ 0.47	$ 0.49

Stockholders' Deficit - Sched34

Stockholders' Deficit - Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Exercise Price 1 [Member]
Exercise price range, lower range limit	$ 0.30
Exercise price range, upper range limit	$ 0.39
Options outstanding, number of options | shares	1,675,500
Options outstanding, weighted average remaining contractual life	9 years
Options outstanding, weighted average exercise price	$ 0.30
Options exercisable, number of options | shares	888,198
Options exercisable, weighted average remaining contractual life	9 years
Options exercisable, weighted average exercise price	$ 0.30
Exercise Price 2 [Member]
Exercise price range, lower range limit	0.40
Exercise price range, upper range limit	$ 0.49
Options outstanding, number of options | shares	311,000
Options outstanding, weighted average remaining contractual life	7 years 7 months 6 days
Options outstanding, weighted average exercise price	$ 0.40
Options exercisable, number of options | shares	311,000
Options exercisable, weighted average remaining contractual life	7 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 0.40
Exercise Price 3 [Member]
Exercise price range, lower range limit	0.50
Exercise price range, upper range limit	$ 0.59
Options outstanding, number of options | shares	251,250
Options outstanding, weighted average remaining contractual life	6 years 10 months 24 days
Options outstanding, weighted average exercise price	$ 0.50
Options exercisable, number of options | shares	251,250
Options exercisable, weighted average remaining contractual life	6 years 10 months 24 days
Options exercisable, weighted average exercise price	$ 0.50
Exercise Price 4 [Member]
Exercise price range, lower range limit	0.60
Exercise price range, upper range limit	$ 0.69
Options outstanding, number of options | shares	467,500
Options outstanding, weighted average remaining contractual life	4 years 2 months 12 days
Options outstanding, weighted average exercise price	$ 0.60
Options exercisable, number of options | shares	451,564
Options exercisable, weighted average remaining contractual life	4 years 2 months 12 days
Options exercisable, weighted average exercise price	$ 0.60
Exercise Price 5 [Member]
Exercise price range, lower range limit	1
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	496,000
Options outstanding, weighted average remaining contractual life	2 years 2 months 12 days
Options outstanding, weighted average exercise price	$ 1
Options exercisable, number of options | shares	496,000
Options exercisable, weighted average remaining contractual life	2 years 2 months 12 days
Options exercisable, weighted average exercise price	$ 1
Exercise Price 6 [Member]
Exercise price range, lower range limit	0.30
Exercise price range, upper range limit	$ 1.25
Options outstanding, number of options | shares	3,201,250
Options outstanding, weighted average remaining contractual life	7 years
Options outstanding, weighted average exercise price	$ 0.48
Options exercisable, number of options | shares	2,398,012
Options exercisable, weighted average remaining contractual life	6 years 3 months 18 days
Options exercisable, weighted average exercise price	$ 0.54

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Nov. 10, 2015USD ($)	Nov. 01, 2015USD ($)ft²	Oct. 28, 2015shares	Oct. 02, 2015USD ($)	Oct. 01, 2015shares	Sep. 30, 2014USD ($)ft²	Nov. 30, 2007USD ($)ft²	Sep. 30, 2015USD ($)shares	Sep. 30, 2014USD ($)ft²	Nov. 05, 2015USD ($)
Area of land | ft²						855	5,500		855
Monthly lease payment						$ 3,094	$ 4,800	$ 73,775	$ 43,200
Lease termination date						Dec. 31, 2017	Dec. 31, 2015
Issuance of common stock shares for services | shares								305,000
Subsequent Event [Member]
Area of land | ft²		833
Monthly lease payment		$ 5,585
Lease termination date		Dec. 31, 2017
Subsequent Event [Member] | Convertible Note from December 2013 [Member]
Debt periodic payment amount	$ 105,760
Debt principal amount										$ 223,000
Subsequent Event [Member] | Convertible Note from April 2, 2015 [Member]
Debt periodic payment amount				$ 100,000
Subsequent Event [Member] | Investor [Member] | Restricted Stock [Member]
Issuance of common stock shares for services | shares			200,000		125,000